Suppr超能文献

系统性硬化症患者胃肠道症状评估与管理的实用方法。

A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis.

机构信息

The Johns Hopkins Hospital, Department of Internal Medicine, USA.

Johns Hopkins University, Division of Gastroenterology, USA.

出版信息

Best Pract Res Clin Rheumatol. 2021 Sep;35(3):101666. doi: 10.1016/j.berh.2021.101666. Epub 2021 Mar 4.

Abstract

The gastrointestinal (GI) tract is the most commonly affected internal organ system in systemic sclerosis (SSc). SSc may lead to impaired function in any region of the GI tract, from the esophagus to the anorectum, which causes significant morbidity as well as mortality in patient subsets. Given the low prevalence of SSc in the community, many rheumatologists may not have a systematic framework for diagnosing or treating the GI complaints in this disease. These practice recommendations aim to summarize and consolidate the current guidelines from the fields of gastroenterology and rheumatology and establish a symptom-based framework for diagnosis and management based on available evidence in the literature. Subject areas that are in need of additional research are also identified.

摘要

胃肠道(GI)是系统性硬化症(SSc)中最常受影响的内脏器官系统。SSc 可能导致从食管到肛门直肠的胃肠道任何部位的功能受损,这在患者亚群中导致了显著的发病率和死亡率。由于 SSc 在社区中的患病率较低,许多风湿病学家可能没有系统的框架来诊断或治疗这种疾病的胃肠道问题。这些实践建议旨在总结和整合来自胃肠病学和风湿病学领域的现有指南,并根据文献中的现有证据建立基于症状的诊断和管理框架。还确定了需要进一步研究的主题领域。

相似文献

1
A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis.
Best Pract Res Clin Rheumatol. 2021 Sep;35(3):101666. doi: 10.1016/j.berh.2021.101666. Epub 2021 Mar 4.
2
Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment.
Curr Opin Rheumatol. 2022 Nov 1;34(6):328-336. doi: 10.1097/BOR.0000000000000899. Epub 2022 Aug 19.
3
Gastrointestinal involvement in systemic sclerosis: An updated review.
Medicine (Baltimore). 2022 Nov 11;101(45):e31780. doi: 10.1097/MD.0000000000031780.
5
Systemic sclerosis and the gut.
Expert Rev Gastroenterol Hepatol. 2013 May;7(4):331-9. doi: 10.1586/egh.13.22.
7
Dysbiosis and Gut Microbiota Modulation in Systemic Sclerosis.
J Clin Rheumatol. 2022 Mar 1;28(2):e568-e573. doi: 10.1097/RHU.0000000000001748.
8
Measuring response in the gastrointestinal tract in systemic sclerosis.
Curr Opin Rheumatol. 2013 Nov;25(6):700-6. doi: 10.1097/01.bor.0000434668.32150.e5.
9
Assessment of gastrointestinal involvement.
Clin Exp Rheumatol. 2003;21(3 Suppl 29):S15-8.
10
Gastrointestinal involvement in systemic sclerosis: an update.
Curr Opin Rheumatol. 2019 Nov;31(6):561-568. doi: 10.1097/BOR.0000000000000645.

引用本文的文献

2
Gastrointestinal manifestations of systemic sclerosis: current approaches and emerging therapies.
Curr Opin Rheumatol. 2025 Jul 15. doi: 10.1097/BOR.0000000000001110.
3
A Case Report and Literature Review on Systemic Sclerosis Manifesting as Melena and Hematochezia.
J Investig Med High Impact Case Rep. 2025 Jan-Dec;13:23247096251348903. doi: 10.1177/23247096251348903. Epub 2025 Jun 19.
5
The role of prokinetics in managing gastrointestinal involvement in SSc: a systematic literature review.
Rheumatology (Oxford). 2025 Jun 1;64(6):3266-3279. doi: 10.1093/rheumatology/keaf064.
7
Evidence for targeting autonomic dysfunction in systemic sclerosis: A scoping review.
J Scleroderma Relat Disord. 2025 Jan 8:23971983241308050. doi: 10.1177/23971983241308050.
8
Twists and turns: The whirl sign in a patient with systemic sclerosis.
Rheumatol Immunol Res. 2024 Oct 21;5(3):179-181. doi: 10.2478/rir-2024-0025. eCollection 2024 Sep.
9
Managing gastrointestinal manifestations in systemic sclerosis, a mechanistic approach.
Expert Rev Clin Immunol. 2024 Jun;20(6):603-622. doi: 10.1080/1744666X.2024.2320205. Epub 2024 Feb 26.
10
If Pills Don't Work, Try Staples: Surgery for Barrett's Esophagus Complicating Progressive Systemic Sclerosis.
Dig Dis Sci. 2023 Oct;68(10):3879-3885. doi: 10.1007/s10620-023-08064-3. Epub 2023 Aug 27.

本文引用的文献

1
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.
Neurology. 2021 Jan 19;96(3):114-122. doi: 10.1212/WNL.0000000000011124. Epub 2020 Nov 3.
3
ACG Clinical Guidelines: Clinical Use of Esophageal Physiologic Testing.
Am J Gastroenterol. 2020 Sep;115(9):1412-1428. doi: 10.14309/ajg.0000000000000734.
4
AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review.
Gastroenterology. 2020 Oct;159(4):1526-1532. doi: 10.1053/j.gastro.2020.06.090. Epub 2020 Jul 15.
5
Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial.
PLoS One. 2020 May 21;15(5):e0232739. doi: 10.1371/journal.pone.0232739. eCollection 2020.
6
Oropharyngeal swallowing functions are impaired in patients with scleroderma.
Clin Exp Rheumatol. 2020 May-Jun;38 Suppl 125(3):169-170. Epub 2019 Dec 27.
8
Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis.
Dig Dis Sci. 2020 Apr;65(4):1134-1143. doi: 10.1007/s10620-019-05830-0. Epub 2019 Sep 23.
9
British Society of Gastroenterology guidelines for oesophageal manometry and oesophageal reflux monitoring.
Gut. 2019 Oct;68(10):1731-1750. doi: 10.1136/gutjnl-2018-318115. Epub 2019 Jul 31.
10
Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study.
Am J Gastroenterol. 2019 Aug;114(8):1265-1274. doi: 10.14309/ajg.0000000000000304.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验